#evaluate(de(' #AdditionalMetaTags# '))#
Endotelix is a spin-off from the University of Geneva and dedicated to providing fast, sensitive and reliable solutions for Antiphospholipid Syndrome including diagnostic tests and treatment options. We are currently developing a new diagnostic test to measure the circulating levels of antiphospholipid antibodies (aPL) as a rapid test (LFA-like). It allows the measuring of anti-ß2GP1 IgG and IgM. This diagnostic test is more sensitive and faster than the current assays. We have also developed an ELISA test for hospital and Research Use Only.
FIF Funding for three new Geneva projects (startupticker.ch)
Diagnostic and cleantech start-ups get the first CHF150,000 “Kicks” of 2020 (startupticker.ch)
Seed Funding Round
Full Clinical Validation of Endotelix's Technology
A Kickers' World, Episode 5 Endotelix CEO Karim Brandt